Amprenavir (Agenerase, GlaxoSmithKline) is a protease inhibitor used to treat HIV infection. It was approved by the Food and Drug Administration on April 15, 1999, for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200 mg, delivered in eight very large gel capsules.
 | |
| Clinical data | |
|---|---|
| Trade names | Agenerase |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a699051 |
| License data |
|
| Routes of administration | oral |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 90% |
| Metabolism | hepatic |
| Elimination half-life | 7.1-10.6 hours |
| Excretion | <3% renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| NIAID ChemDB | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.262.589 |
| Chemical and physical data | |
| Formula | C25H35N3O6S |
| Molar mass | 505.628 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Production of amprenavir was discontinued by the manufacturer December 31, 2004; a prodrug version (fosamprenavir) is available.
See also
- Fosamprenavir, a prodrug of amprenavir
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |